Novavax, Inc. (BUL:NVV1)
Bulgaria · Delayed Price · Currency is EUR | Market Cap | 1.31B +25.4% |
| Revenue (ttm) | 362.50M -61.3% |
| Net Income | -67.57M |
| EPS | -0.42 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 760 |
| Open | 9.65 |
| Previous Close | 7.95 |
| Day's Range | 9.58 - 9.65 |
| 52-Week Range | 6.36 - 9.65 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Novavax
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in ... [Read more]
News
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference: Jefferies London H...
Novavax price target lowered to $16 from $18 at B. Riley
B. Riley lowered the firm’s price target on Novavax (NVAX) to $16 from $18 and keeps a Buy rating on the shares. The company reported “strong, execution-focused, in-line” Q3 results,…
Novavax price target lowered to $7 from $8 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Novavax (NVAX) to $7 from $8 and keeps an Underperform rating on the shares.
Novavax Earnings Call Transcript: Q3 2026
Q3 revenue was $68 million and net loss narrowed to $31 million. Sanofi’s $125 million trial milestone lifted FY2026 adjusted revenue guidance to a $400 million midpoint, while cost reductions and partner milestones support runway into 2029.
Novavax Earnings release: Q3 2026
Novavax released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Novavax Slides: Q3 2026
Novavax has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Novavax Quarterly report: Q3 2026
Novavax has published its Q3 2026 quarterly earnings report on November 5, 2026.
Novavax raises FY26 adjusted revenue view to $385M-$415M from $235M-$275M
FY26 consensus $383.89M.
Novavax reports Q3 EPS (19c), consensus (42c)
Reports Q3 revenue $68.3M, consensus $50.42M. “This quarter, we continued to execute across all three pillars of our strategy,” said John C. Jacobs, President and Chief Executive Officer, Novavax (NVA...
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and...
Novavax earns $125M milestone as Sanofi launches Phase 3 vaccine trial
Novavax (NVAX) has earned a $125M milestone payment with the initiation of Sanofi’s (SNY) Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax’s COVID-19 vaccine, Nuvaxovid. Sanofi’s...
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi'...
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. fin...
Novavax shareholder Shah Capital to step back from activist role
Shah Capital, one of Novavax's top shareholders, said on Friday it no longer seeks to influence control of the vaccine maker after restructuring into a family office.
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Novavax price target raised to $8 from $7 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Novavax (NVAX) to $8 from $7 and keeps a Sell rating on the shares. The firm updated models in the…
Novavax price target raised to $8 from $7 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Novavax (NVAX) to $8 from $7 and keeps an Underperform rating on the shares as part of a Q3 earnings…
Novavax Stock (NVAX) Plunges After WHO Calms Plague Fears
Shares of vaccine developer Novavax ($NVAX) plunged on Tuesday after the World Health Organization said that the risk of a wider plague outbreak remains low. The drop reversed part of…
Novavax Transcript: Citigroup’s Biopharma Back to School Summit 2026
The discussion highlighted a strategic shift to out-licensing and partnerships, with Sanofi and Pfizer driving near-term milestones and global expansion. Matrix-M's potential in oncology and infectious diseases is being explored, while NUVAXOVID's U.S. launch and combination vaccine prospects are set to drive growth.
Novavax Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A major strategic pivot has shifted focus to licensing and partnerships, with Matrix-M technology now central to both infectious disease and oncology pipelines. Key alliances with top pharma, strong financial milestones, and a leaner structure position the company for sustainable growth and global impact.
Novavax to Participate in September Investor Conferences
GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conferences: 2026 Cantor Globa...
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
Novavax’s (NVAX) partners have received approvals for the Nuvaxovid formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European ...
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
COVID-19 remains a public health challenge, particularly among older adults and high-risk populations 1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable toler...